Literature DB >> 1606352

Sex steroids and cancer in older women.

T R Varma1.   

Abstract

Menopause and hormone replacement therapy (HRT) continue to be controversial subjects. The main concern is the potential risk of prolonged HRT and the possible development of endometrial and breast carcinoma. There is no obvious evidence at present to suggest that HRT increases endometrial carcinoma provided the patient receives progestogen for a period of 10 or more days (usual period is 12 days) during each month. However the breast does not seem to enjoy this safety margin and there is some concern about possible increase in the incidence of breast cancer if the treatment period is longer than 5 years. The increase in the risk is higher after 15 years of estrogen use. There is no obvious adverse effect on the ovary or on the cervix following HRT.

Entities:  

Mesh:

Year:  1992        PMID: 1606352     DOI: 10.2165/00002512-199202030-00003

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  104 in total

1.  Pre-menopausal cystic hyperplasia and endometrial carcinoma.

Authors:  J M McBRIDE
Journal:  J Obstet Gynaecol Br Emp       Date:  1959-04

2.  Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age.

Authors:  D L Hemsell; J M Grodin; P F Brenner; P K Siiteri; P C MacDonald
Journal:  J Clin Endocrinol Metab       Date:  1974-03       Impact factor: 5.958

3.  Continuous treatment with natural oestrogens and progestogens. A method to avoid endometrial stimulation.

Authors:  B Staland
Journal:  Maturitas       Date:  1981-08       Impact factor: 4.342

4.  Intracellular estradiol, estrone and estrogen receptor levels in endometria from postmenopausal women receiving estrogens and progestins.

Authors:  R J King; G Dyer; W P Collins; M I Whitehead
Journal:  J Steroid Biochem       Date:  1980-04       Impact factor: 4.292

5.  Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study.

Authors:  I Persson; H O Adami; L Bergkvist; A Lindgren; B Pettersson; R Hoover; C Schairer
Journal:  BMJ       Date:  1989-01-21

6.  Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy.

Authors:  K Hunt; M Vessey; K McPherson; M Coleman
Journal:  Br J Obstet Gynaecol       Date:  1987-07

Review 7.  Hormone replacement therapy and breast cancer.

Authors:  R D Gambrell
Journal:  Maturitas       Date:  1987-08       Impact factor: 4.342

8.  Recent and past use of conjugated estrogens in relation to adenocarcinoma of the endometrium.

Authors:  S Shapiro; D W Kaufman; D Slone; L Rosenberg; O S Miettinen; P D Stolley; N B Rosenshein; W G Watring; T Leavitt; R C Knapp
Journal:  N Engl J Med       Date:  1980-08-28       Impact factor: 91.245

9.  Noncontraceptive estrogen use and the occurrence of ovarian cancer.

Authors:  N S Weiss; J L Lyon; S Krishnamurthy; S E Dietert; J M Liff; J R Daling
Journal:  J Natl Cancer Inst       Date:  1982-01       Impact factor: 13.506

10.  Menopausal estrogen use and risk of breast cancer.

Authors:  L A Brinton; R N Hoover; M Szklo; J F Fraumeni
Journal:  Cancer       Date:  1981-05-15       Impact factor: 6.860

View more
  1 in total

Review 1.  Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use.

Authors:  S Patel; A R Lyons; D J Hosking
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.